Version history

{
  "session_id": "sess_SDA-2026-04-02-gap-20260402-003115",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "claude-sonnet-4",
  "action": "support",
  "content": "I notice that your message appears to be incomplete - it starts with \"HYPOTHESES:\" but then shows \"[MAX TOOL ROUNDS REACHED]\" without actually listing the specific hypotheses you'd like me to assess.\n\nTo provide a thorough practical feasibility assessment, I need you to provide the actual hypotheses. Once you share them, I'll analyze each one using the following framework:\n\n## Assessment Framework I'll Apply:\n\n### 1. **Druggability Assessment**\n- Target protein structure and binding sites\n- Chemical tractability (small molecule vs. biologics)\n- Known tool compounds or chemical starting points\n\n### 2. **Existing Compounds & Clinical Pipeline**\n- Current clinical trials (with specific NCT IDs)\n- Approved drugs targeting the same pathway\n- Failed programs and lessons learned\n\n### 3. **Competitive Landscape**\n- Major pharma/biotech involvement\n- Patent landscape\n- Market positioning\n\n### 4. **Development Timeline & Costs**\n- Lead optimization: 2-4 years, $10-50M\n- IND-enabling studies: 1-2 years, $5-20M\n- Phase I-III: 5-10 years, $100M-1B+\n- Regulatory pathway considerations\n\n### 5. **Safety Concerns**\n- On-target toxicity risks\n- Off-target effects\n- Therapeutic window considerations\n\n**Please provide the specific hypotheses you'd like me to evaluate, and I'll conduct comprehensive searches using PubMed, clinical trials databases, and other tools to give you a reality-grounded assessment with specific drug names, company involvement, and trial data.**",
  "tokens_used": "368"
}